GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Price-to-Free-Cash-Flow

SRZN (Surrozen) Price-to-Free-Cash-Flow : N/A (As of Apr. 13, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Surrozen Price-to-Free-Cash-Flow?

As of today (2025-04-13), Surrozen's share price is $9.00. Surrozen's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-7.00. Hence, Surrozen's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Surrozen's Price-to-Free-Cash-Flow or its related term are showing as below:

SRZN's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 28.78
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Surrozen's Free Cash Flow per Share for the three months ended in Dec. 2024 was $1.07. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-7.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 41.70% per year.

During the past 5 years, Surrozen's highest 3-Year average Free Cash Flow per Share Growth Rate was 41.70% per year. The lowest was -16.30% per year. And the median was 12.70% per year.


Surrozen Price-to-Free-Cash-Flow Historical Data

The historical data trend for Surrozen's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Price-to-Free-Cash-Flow Chart

Surrozen Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
- - - - -

Surrozen Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Surrozen's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Surrozen's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surrozen's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Surrozen's Price-to-Free-Cash-Flow falls into.


;
;

Surrozen Price-to-Free-Cash-Flow Calculation

Surrozen's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=9.00/-6.999
=N/A

Surrozen's Share Price of today is $9.00.
Surrozen's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Surrozen  (NAS:SRZN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Surrozen Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Surrozen's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Surrozen Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Executives
Charles O Williams officer: Chief Financial Officer C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Tim Kutzkey director, 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Anna Berkenblit director 830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md director, 10 percent owner 1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai director 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh officer: Chief Scientific Officer 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory other: Former VP Business Development C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove officer: Chief Medical Officer 1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel other: Former Director 4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse director 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158